GC Green Cross Administers First Participant Dose in Phase 1 Clinical Trial of COVID-19 mRNA Vaccine

COVID-19 Vaccine Development Progressing Smoothly Using Proprietary mRNA Platform

GC Green Cross announced on January 30 that it has completed the first dose administration for a participant in the domestic Phase 1 clinical trial of its COVID-19 mRNA vaccine candidate, 'GC4006A'.

GC Green Cross received approval for its Phase 1 IND (Investigational New Drug) application from the Ministry of Food and Drug Safety in December of last year. In this trial, the company is evaluating the safety and immunogenicity of the vaccine in healthy adults aged 19 to 64.

Exterior view of GC Green Cross headquarters in Yongin, Gyeonggi Province. GC Green Cross

GC4006A is a vaccine candidate developed based on GC Green Cross's proprietary mRNA platform. In preclinical studies, it demonstrated the potential for further development by showing antibody production and immune responses at levels comparable to existing commercial vaccines.

The company explained that, based on the results of the Phase 1 clinical trial, it plans to apply for a Phase 2 IND in the second half of this year.

Jaeuk Jung, Head of R&D at GC Green Cross, stated, "The launch of our first clinical trial for a vaccine utilizing our mRNA platform is highly significant. We will thoroughly verify its safety and efficacy to ensure the successful development of the vaccine."

Meanwhile, in December of last year, GC Green Cross was selected as a company to receive research support for its Phase 1 clinical trial under the 'Pandemic Preparedness mRNA Vaccine Development Support Project' organized by the Korea Disease Control and Prevention Agency and the Korea Health Industry Development Institute. The company continues its research efforts to develop a domestically produced mRNA vaccine.

This content was produced with the assistance of AI translation services.